亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma

作者
Yan Qing Zhu,Maoxuan Liu,Xiaokai Fan,Yingying Xu,Xueling Diao,Jiacheng Bi,Xiaochun Wan,Yehuda G. Assaraf,Hang Fai Kwok,Liang Chen
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:14 (3): e010841-e010841 被引量:5
标识
DOI:10.1136/jitc-2024-010841
摘要

Background Immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC). However, the frequent emergence of treatment resistance significantly limits the clinical efficacy of HCC immunotherapy. The molecular mechanisms underlying therapy resistance remain poorly understood. Methods To delineate the immune impact of nuclear factor erythroid 2-related factor 2 (Nrf2) inhibition, we integrated allograft tumor models with bulk and single-cell RNA sequencing analyses. Biochemical assays were performed to investigate the mechanisms underlying Nrf2 inhibition in immune resistance. The combined activity of Nrf2 inhibition with anti-programmed death-1 (PD-1) antibody and CAR-T cell therapy was also explored in vivo. Results We show that brusatol (BRU), a specific inhibitor of Nrf2, an emerging regulator of the tumor immune microenvironment, potentiates antitumor immunity in HCC mouse models. Mechanistically, inhibition of Nrf2 downregulates surface programmed death ligand-1 (PD-L1) expression via transcriptional repression in tumor cells, while upregulating major histocompatibility complex (MHC)-I expression via nuclear factor kappa-light-chain-enhancer of activated B cells activation. Inhibition of Nrf2 in tumor cells enhances the activation of immune-related signaling pathways and promotes CD8 + T-cell infiltration into tumor tissues. Furthermore, inhibition of Nrf2 with BRU significantly enhances the efficacy of PD-1 antibody and CAR-T cells against HCC in vivo, indicating that therapeutic targeting of Nrf2 in HCC cells sensitizes them to ICIs and CAR-T immunotherapies. Conclusions Our findings offer a novel strategy to enhance HCC immunotherapy by blocking Nrf2, which has the potential to address the low response rates observed with current HCC immunotherapies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LHY完成签到,获得积分10
7秒前
11秒前
香蕉乐曲完成签到,获得积分10
30秒前
54秒前
null的应助被科研通管家采纳,获得10
1分钟前
沉静的愫完成签到,获得积分10
1分钟前
1分钟前
ww完成签到,获得积分10
1分钟前
ww发布了新的文献求助10
1分钟前
1分钟前
adgn发布了新的文献求助10
2分钟前
老实的石头完成签到,获得积分10
2分钟前
2分钟前
个性鹭洋完成签到,获得积分10
2分钟前
丘比特的应助被adgn采纳,获得10
2分钟前
2分钟前
戴肉肉完成签到 ,获得积分10
3分钟前
深情安青的应助被科研通管家采纳,获得10
3分钟前
专注湘完成签到,获得积分10
3分钟前
范特西完成签到 ,获得积分10
3分钟前
忍冬完成签到,获得积分10
3分钟前
就吃一小口完成签到 ,获得积分10
4分钟前
AlexMoradi452发布了新的文献求助50
4分钟前
友好怜菡完成签到,获得积分10
4分钟前
跳跃的咖啡豆完成签到,获得积分10
4分钟前
4分钟前
4分钟前
盐水菠萝完成签到,获得积分10
4分钟前
rubbish发布了新的文献求助10
4分钟前
Wei发布了新的文献求助10
4分钟前
盐水菠萝发布了新的文献求助10
4分钟前
深情安青的应助被林楚棋采纳,获得10
4分钟前
陈淋完成签到,获得积分10
4分钟前
小巧的孤丹完成签到,获得积分10
4分钟前
null的应助被科研通管家采纳,获得10
5分钟前
大模型的应助被科研通管家采纳,获得10
5分钟前
5分钟前
所所的应助被科研通管家采纳,获得10
5分钟前
5分钟前
null的应助被科研通管家采纳,获得10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173069
求助须知:如何正确求助?哪些是违规求助? 9565519
关于积分的说明 21780335
捐赠科研通 7765068
什么是DOI,文献DOI怎么找? 3431528
关于科研通互助平台的介绍 2555609
邀请新用户注册赠送积分活动 2476668